ArticleBMC cancer2024

Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand.

Thanate Dajsakdipon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.